WHO issues guidelines on the treatment of children with MIS-C

Nov. 24, 2021

The World Health Organization (WHO) has issued updated guidelines on the management of multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C).

MIS-C is a rare but serious condition in which children with COVID-19 develop inflammation affecting different organs of the body. Children with this condition need specialized care and may need to be admitted to intensive care. Although MIS-C is a serious condition, with the right medical care, children with this condition recover.

In addition to supportive treatment and care, the WHO’s updated guidelines recommend the use of corticosteroids in hospitalized children and adolescents with this condition.

The recommendation is based on three observational studies, pooling data from 885 patients in total.

Overall, children remain at a low of risk of developing severe or critical COVID-19, but certain underlying conditions make children more susceptible to severe disease. The most commonly reported of these conditions are obesity, chronic lung disease (including asthma), cardiovascular disease and immunosuppression.

Visit the WHO for more news